Correction to: J Exp Clin Cancer Res 33, 99 (2014)
https://doi.org/10.1186/s13046-014-0099-0
Anzeige
Following publication of the article [1], the authors identified errors in Figs. 3, 4 and 6; specifically panels Fig. 3c (HGC-27 ‘untreated’), Fig. 4c (GES ‘untreated’), Fig. 6c and d. The corrections do not change the results or the conclusions of this paper.
Fig. 3
Enforced expression of miR-133b can inhibit GC cell migration and invasion. (A) The pictures of wound healing and the percentages of open wound of HGC-27 cells at 0, 24, 48 hours after scratching. Data are shown as mean + s.d. (n = 3); ** indicates P-value <0.01. (B) The pictures of wound healing and the percentages of open wound of MGC-803 cells at 0, 24, 48 hours after scratching. Data are shown as mean + s.d. (n = 3); ** indicates P-value <0.01. (C) The invaded HGC-27 cells in the Matrigel transwell invasion assay. Data are shown as mean + s.d. (n = 3); ** indicates P-value <0.01. (D) The invaded MGC-803 cells in the Matrigel transwell invasion assay. Data are shown as mean + s.d. (n = 3); ** indicates P-value <0.01
Fig. 4
Knockdown of miR-133b in GES cells can promote cell proliferation and migration. (A) Inhibition of miR-133b in GES cells was confirmed by qRT-PCR. (B) The cell growth of GES cells at day 0, 1, 2, 3, 4 post transfection which was detected by CCK-8 assay. Data are shown as mean ± s.d. (n = 3); * indicates P-value <0.05;** indicates P-value <0.01. (C) The invaded GES cells in the Matrigel transwell invasion assay. Data are shown as mean + s.d. (n = 3); ** indicates P-value <0.01
Fig. 6
Knock down of FSCN1 can inhibit GC cell growth and invasion. (A) Western blot analysis of FSCN1 expression in HGC-27 and MGC-803 cells transfected with negative control or FSCN1 siRNAs. (B) The cell growth of HGC-27 and MGC-803 cells at day 0, 1, 2, 3, 4 post transfection which was detected by CCK-8 assay. Data are shown as mean + s.d. (n = 3); * indicates P-value <0.05. ** indicates P-value <0.01. *** indicates P-value <0.001. (C) The invaded HGC-27 cells in the Matrigel transwell invasion assay. Data are shown as mean + s.d. (n = 3); ** indicates P-value <0.01. (D) The invaded MGC-803 cells in the Matrigel transwell invasion assay. Data are shown as mean + s.d. (n = 3); ** indicates P-value <0.01. (E) Western blot analysis of FSCN1 expression in 6 pairs of GC tissues (C) and the adjacent non-neoplastic tissues (N)
×
×
×
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.
Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.
Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
